{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT00232050",
      "orgStudyIdInfo": {
        "id": "CIGE025A1304"
      },
      "organization": {
        "fullName": "Novartis",
        "class": "INDUSTRY"
      },
      "briefTitle": "Study of Omalizumab in Moderate to Severe Bronchial Asthma",
      "officialTitle": "Study of Omalizumab in Moderate to Severe Bronchial Asthma"
    },
    "statusModule": {
      "statusVerifiedDate": "2011-10",
      "overallStatus": "COMPLETED",
      "expandedAccessInfo": {
        "hasExpandedAccess": false
      },
      "startDateStruct": {
        "date": "2002-10"
      },
      "primaryCompletionDateStruct": {
        "date": "2005-05",
        "type": "ACTUAL"
      },
      "completionDateStruct": {
        "date": "2005-05",
        "type": "ACTUAL"
      },
      "studyFirstSubmitDate": "2005-10-03",
      "studyFirstSubmitQcDate": "2005-10-03",
      "studyFirstPostDateStruct": {
        "date": "2005-10-04",
        "type": "ESTIMATED"
      },
      "lastUpdateSubmitDate": "2011-10-24",
      "lastUpdatePostDateStruct": {
        "date": "2011-10-25",
        "type": "ESTIMATED"
      }
    },
    "sponsorCollaboratorsModule": {
      "leadSponsor": {
        "name": "Novartis",
        "class": "INDUSTRY"
      },
      "collaborators": [
        {
          "name": "Daiichi Sankyo Co., Ltd.",
          "class": "INDUSTRY"
        }
      ]
    },
    "descriptionModule": {
      "briefSummary": "This study will evaluate the safety and efficacy of omalizumab up to 16 weeks in adult patients with moderate to severe bronchial asthma."
    },
    "conditionsModule": {
      "conditions": [
        "Asthma"
      ],
      "keywords": [
        "Asthma, IgE, Omalizumab"
      ]
    },
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "designInfo": {
        "allocation": "RANDOMIZED",
        "interventionModel": "PARALLEL",
        "primaryPurpose": "TREATMENT",
        "maskingInfo": {
          "masking": "DOUBLE"
        }
      },
      "enrollmentInfo": {
        "count": 327,
        "type": "ACTUAL"
      }
    },
    "armsInterventionsModule": {
      "interventions": [
        {
          "type": "DRUG",
          "name": "Omalizumab"
        }
      ]
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "Morning peak expiratory flow (PEF) at baseline and end of treatment."
        }
      ],
      "secondaryOutcomes": [
        {
          "measure": "Pulmonary function parameters measured by spirometer"
        },
        {
          "measure": "Frequency of rescue medication use"
        },
        {
          "measure": "Symptom score"
        },
        {
          "measure": "Activities of daily living score"
        },
        {
          "measure": "Nighttime sleep score"
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Inclusion Criteria:\n\n* Allergic asthma patients\n* Inadequately controlled patients\n\nExclusion Criteria:\n\n* \\- History of severe anaphylactoid or anaphylactic reactions\n* Previous treatment with omalizumab\n* History of cancer or cancer\n\nOther protocol-defined exclusion criteria may apply",
      "sex": "ALL",
      "minimumAge": "20 Years",
      "maximumAge": "75 Years",
      "stdAges": [
        "ADULT",
        "OLDER_ADULT"
      ]
    },
    "contactsLocationsModule": {
      "overallOfficials": [
        {
          "name": "Novartis Pharmaceuticals Japan",
          "affiliation": "Novartis Pharmaceuticals Japan",
          "role": "STUDY_CHAIR"
        }
      ]
    }
  },
  "derivedSection": {
    "miscInfoModule": {
      "versionHolder": "2026-02-04"
    },
    "conditionBrowseModule": {
      "meshes": [
        {
          "id": "D001249",
          "term": "Asthma"
        },
        {
          "id": "C562694",
          "term": "Epilepsy, Idiopathic Generalized"
        }
      ],
      "ancestors": [
        {
          "id": "D001982",
          "term": "Bronchial Diseases"
        },
        {
          "id": "D012140",
          "term": "Respiratory Tract Diseases"
        },
        {
          "id": "D008173",
          "term": "Lung Diseases, Obstructive"
        },
        {
          "id": "D008171",
          "term": "Lung Diseases"
        },
        {
          "id": "D012130",
          "term": "Respiratory Hypersensitivity"
        },
        {
          "id": "D006969",
          "term": "Hypersensitivity, Immediate"
        },
        {
          "id": "D006967",
          "term": "Hypersensitivity"
        },
        {
          "id": "D007154",
          "term": "Immune System Diseases"
        }
      ]
    },
    "interventionBrowseModule": {
      "meshes": [
        {
          "id": "D000069444",
          "term": "Omalizumab"
        }
      ],
      "ancestors": [
        {
          "id": "D000888",
          "term": "Antibodies, Anti-Idiotypic"
        },
        {
          "id": "D000906",
          "term": "Antibodies"
        },
        {
          "id": "D007136",
          "term": "Immunoglobulins"
        },
        {
          "id": "D007162",
          "term": "Immunoproteins"
        },
        {
          "id": "D001798",
          "term": "Blood Proteins"
        },
        {
          "id": "D011506",
          "term": "Proteins"
        },
        {
          "id": "D000602",
          "term": "Amino Acids, Peptides, and Proteins"
        },
        {
          "id": "D061067",
          "term": "Antibodies, Monoclonal, Humanized"
        },
        {
          "id": "D000911",
          "term": "Antibodies, Monoclonal"
        },
        {
          "id": "D012712",
          "term": "Serum Globulins"
        },
        {
          "id": "D005916",
          "term": "Globulins"
        }
      ]
    }
  },
  "hasResults": false
}